MMTS MULTI MINI TABLET SYSTEM
LIVE

Serial Number

97689880

Owner

ADARE PHARMACEUTICALS S.R.L.

Attorney

Robert S. Broder

Filing Date

Nov 23, 2022

Add to watchlist:

No watchlists yet
View on USPTO

MMTS MULTI MINI TABLET SYSTEM Trademark

Serial Number: 97689880 • Registration: 7683627

MMTS MULTI MINI TABLET SYSTEM is a trademark filed by ADARE PHARMACEUTICALS S.R.L. on November 23, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

ADARE PHARMACEUTICALS S.R.L. (11 trademarks)

VIA MARTIN LUTHER KING, 13
MILAN 20042 , IT

Entity Type: 16

Trademark Details

Filing Date

November 23, 2022

Registration Date

February 11, 2025

Published for Opposition

June 11, 2024

Goods & Services

Manufacturing services to the specification of others in the pharmaceutical field and in the veterinary field, in particular in the field of pharmaceutical active substance delivery systems, including customized release, taste masked release, immediate release, pulsatile release, extended release, sustained release, and delayed release systems; clinical manufacturing of drug compositions for others to support clinical trials; manufacturing process consulting services for others relating to technology scale-up and integration of technology into manufacturing processes

Pharmaceutical and veterinary pharmaceutical preparations, in particular drug delivery compositions, drug carriers and drug delivery agents, capsules, sachets and sprinkles for pharmaceutical purposes, comprising multiparticulates or multiple units, used for the treatment of disorders or diseases in the gastrointestinal tract, in the digestive system, in the gut, in the immune systems, in the cardiovascular system, in the respiratory tract, in the blood, in the metabolism, in the nervous system, in the cognition, in the behavior, and in the reproductive tract, gastrointestinal infections, diarrhea, irritable bowel syndrome, inflammatory bowel syndrome disease, enterocolitis, enteritis, ulcerative colitis, cardiovascular disorders, hypertension, thrombosis, vasoconstriction, asthma, inflammation of respiratory tract, asthma, bronchoconstriction, [ thrombonemia, ipertriglyceremia, ipercholesterolemia, iperlipoproteinemia, ] * thrombocythemia ,hypertriglyceridemia, hypercholesterolemia, hyperlipoproteinemia, * blood anemia, hypocalcemia, diabetes, diabetic peripheral neuropathy, dyskinesia, hyperkinetic movements, enzyme deficiency, pancreatitis, pancreatectomy, steatorrhea, cystic fibrosis, Paget's disease, bacterial infections, viral infections, fungal infections, osteoporosis, cancer, mucosal and systemic inflammation, functional disease, abdominal pain, allergy, obesity, muscle spasticity, spasms, convulsion, dysthymia, schizophrenia, degenerative dementia, [ Alzheimer, ] * Alzheimer's, * stress, anxiety, depression, mood disturbance, sociability disturbance, sleep disturbance, psychological disturbance, attention deficit hyperactivity disorder, addiction, fibromyalgia, obsessive-compulsive disorders, pain, peripheral neuropathic pain, post-surgical pain, back-pain, osteoarthritis

Research and development services in the pharmaceutical field and in the veterinary field, in particular in the field of pharmaceutical active substance delivery systems; research and development services for the preparation of multiparticulates or multiple units dosage forms including capsules, sachets, sprinkles; research and development in the area of delivery systems with customized release, taste masked release, immediate release, pulsatile release, extended release, sustained release, and delayed release; scientific research and development in the area of stability testing, physical characterization, in-vitro release testing

Filing History

NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
Aug 12, 2025 NURC
CORRECTION UNDER SECTION 7 - PROCESSED
Jul 24, 2025 COC.
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jul 14, 2025 APRE
TEAS SECTION 7 REQUEST RECEIVED
Feb 18, 2025 ES7R
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Feb 11, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Feb 11, 2025 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Jan 22, 2025 DP1B
NOTICE OF ALLOWANCE CANCELLED
Jan 22, 2025 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Dec 9, 2024 D1BR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 5, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Dec 5, 2024 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 5, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 5, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Dec 5, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Dec 5, 2024 COAR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 6, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 11, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jun 11, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 22, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 6, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
May 6, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 6, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
May 6, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 6, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 2, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 2, 2024 CRFA
ASSIGNED TO LIE
May 2, 2024 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 12, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 12, 2023 GNRN
NON-FINAL ACTION E-MAILED
Sep 12, 2023 GNRT
NON-FINAL ACTION WRITTEN
Sep 12, 2023 CNRT
ASSIGNED TO EXAMINER
Sep 6, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 15, 2022 NWOS
NEW APPLICATION ENTERED
Nov 26, 2022 NWAP